Login to Your Account

Clinic Roundup

Tuesday, October 23, 2012

• Methylgene Inc., of Montreal, presented Phase I data for MGCD290, an antifungal compound, showing that all doses and schedules of the drug were tolerated with no severe or serious adverse events, and that pharmacokinetics were dose dependent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription